今日上午,东阳光长江药业(01558)股价大涨5.05%,报9.04港元,主要受两大利好因素推动。
一方面,上交所及深交所公布,东阳光长江药业将自9月10日起调入沪深港通下的港股通标的名单。这意味着该股将获得更多内地资金流入,提振了市场对其投资需求和价格预期。市场预期在未来一段时间内,随着内地资金持续流入,该股仍有上升空间。
另一方面,东阳光长江药业上半年以胰岛素为代表的慢病疗程板块营业额大幅增长140.7%至1.8亿元,显示公司在主力产品线业绩向好,为未来发展注入新动力。优异的业绩增长也强化了市场对该股中长期投资价值的看好预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.